CASI Pharmaceuticals (CASIF) Intangibles (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Intangibles came in at $2.5 million in Q4 2025, up 0.57% YoY from $2.5 million in Q4 2024, and up 1003.12% on a QoQ basis from $224000.0 in Q3 2025.
CASI Pharmaceuticals (CASIF) Intangibles (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Intangibles data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Intangibles rose 0.57% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 0.57% YoY) and the FY2025 annual result came in at $2.5 million, up 0.57% from the prior year.
- Intangibles climbed to $2.5 million in Q4 2025, from $224000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $1.8 billion in Q4 2023 to a low of $224000.0 in Q3 2025.
- A 5-year average of $362.8 million and a median of $2.5 million in 2025 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles soared 172900.94% — and 2025, when it slumped 99.98%.
- Tracing CASIF's Intangibles over 5 years: stood at $16.0 million in 2021, then slumped by 93.37% to $1.1 million in 2022, then soared by 172900.94% to $1.8 billion in 2023, then sank by 99.87% to $2.5 million in 2024, then grew by 0.57% to $2.5 million in 2025.
- The last three Intangibles figures came in at $2.5 million (Q4 2025), $224000.0 (Q3 2025), and $230000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 214.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 224,000.00 |
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 233.00 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Jun 30, 2024 | 1.36 Bn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 1.84 Bn |
| Jun 30, 2023 | 537.00 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 16.03 Mn |